LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 733

Search options

  1. Article ; Online: Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19.

    Kow, Chia Siang / Ramachandram, Dinesh Sangarran / Hasan, Syed Shahzad

    Inflammopharmacology

    2023  Volume 31, Issue 4, Page(s) 2077–2078

    MeSH term(s) Humans ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/prevention & control ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; COVID-19 ; Anticoagulants/therapeutic use ; Risk Factors
    Chemical Substances Interleukin 1 Receptor Antagonist Protein ; Anticoagulants
    Language English
    Publishing date 2023-04-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1080058-x
    ISSN 1568-5608 ; 0925-4692
    ISSN (online) 1568-5608
    ISSN 0925-4692
    DOI 10.1007/s10787-023-01203-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Venous Thromboembolism in Patients Hospitalized for COVID-19 in a Non-Intensive Care Unit.

    Mackiewicz-Milewska, Magdalena / Cisowska-Adamiak, Małgorzata / Pyskir, Jerzy / Świątkiewicz, Iwona

    Journal of clinical medicine

    2024  Volume 13, Issue 2

    Abstract: ... for COVID-19 in a non-intensive care unit (non-ICU). Consecutive adult patients with COVID-19 hospitalized ... CoV-2) may contribute to venous thromboembolism (VTE) with adverse effects on the course of COVID-19 ... Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS ...

    Abstract Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may contribute to venous thromboembolism (VTE) with adverse effects on the course of COVID-19. The purpose of this study was to investigate an incidence and risk factors for VTE in patients hospitalized for COVID-19 in a non-intensive care unit (non-ICU). Consecutive adult patients with COVID-19 hospitalized from November 2021 to March 2022 in the isolation non-ICU at our center were included in the study. Incidence of VTE including pulmonary embolism (PE) and deep vein thrombosis (DVT), clinical characteristics, and D-dimer plasma levels during the hospitalization were retrospectively evaluated. Among the 181 patients (aged 68.8 ± 16.2 years, 44% females, 39% Delta SARS-CoV-2 variant, 61% Omicron SARS-CoV-2 variant), VTE occurred in 29 patients (VTE group, 16% of the entire cohort). Of them, PE and DVT were diagnosed in 15 (8.3% of the entire cohort) and 14 (7.7%) patients, respectively. No significant differences in clinical characteristics were observed between the VTE and non-VTE groups. On admission, median D-dimer was elevated in both groups, more for VTE group (1549 ng/mL in VTE vs. 1111 ng/mL in non-VTE,
    Language English
    Publishing date 2024-01-17
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13020528
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Venous Thromboembolism and Associated Factors in Hospitalized Patients with COVID-19 at Addis Ababa COVID-19 Field Hospital, Ethiopia.

    Haile, Abel Teklit / Haile, Robel Gemechu / Gebrehiwot, Esrom Hagos / Abeje, Eden Workalemahu

    Infection and drug resistance

    2024  Volume 17, Page(s) 305–317

    Abstract: ... factors in 19 patients admitted to Addis Ababa's field hospital for COVID-19.: Objective: To identify ... of COVID-19.: Methods: To determine the risks of VTE patients, an institution-based case control ... Results: Significant factors associated with the development of VTE in COVID-19 patients included having ...

    Abstract Background: The association of COVID-19 with venous thromboembolism is of particular interest as there are reports that have associated thrombotic events with the pandemic. COVID-19 may predispose to venous thromboembolism. There is initial evidence suggesting that individuals with COVID-19 may be more prone to developing venous thromboembolism (VTE). This study aims to assess venous thromboembolism and associated factors in 19 patients admitted to Addis Ababa's field hospital for COVID-19.
    Objective: To identify associated factors that affect the development of thromboembolism in patients admitted with the diagnosis of COVID-19.
    Methods: To determine the risks of VTE patients, an institution-based case control research was conducted using SPSS version 26, multivariable binary logistic regression analysis was used.
    Results: Significant factors associated with the development of VTE in COVID-19 patients included having a severe case (AOR = 0.38, 95% CI = 0.149-0.961), risk factors for VTE (AOR = 2.57, 95% CI = 1.18-5.33), diabetes (AOR = 3.745, 95% CI = 1.715-8.176), chest pain (AOR = 4.13, 95% CI = 1.89-9), stage 1 hypertension levels (AOR = 3.67, 95% CI = 1.37-9.836), and hospital anticoagulation (AOR = 11.78, 95% CI = 5.25-26.4).
    Conclusion: The results of VTE in individuals with COVID-19 imply a direct association between severe COVID-19 and diabetes, having risk factors, hypertension, and hospital anticoagulation.
    Language English
    Publishing date 2024-01-26
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2494856-1
    ISSN 1178-6973
    ISSN 1178-6973
    DOI 10.2147/IDR.S449401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Venous thromboembolism in patients hospitalised with COVID-19 in England.

    Roberts, Lara N / Navaratnam, Annakan V / Arya, Roopen / Briggs, Tim W R / Gray, William K

    Thrombosis research

    2022  Volume 213, Page(s) 138–144

    Abstract: ... in patients hospitalised with COVID-19 in England.: Methods: This was an exploratory retrospective analysis ... Over the 13 months, 374,244 unique patients had a diagnosis of COVID-19 during a hospital stay ... in England with a diagnosis of COVID-19 who had a hospital stay that was completed between 1st March 2020 and ...

    Abstract Background: The aim of this study was to detail the incidence of venous thromboembolism (VTE) in patients hospitalised with COVID-19 in England.
    Methods: This was an exploratory retrospective analysis of observational data from the Hospital Episode Statistics dataset for England. All patients aged ≥18 years in England with a diagnosis of COVID-19 who had a hospital stay that was completed between 1st March 2020 and 31st March 2021 were included. A recorded diagnosis of VTE during the index stay or during a subsequent admission in the six weeks following discharge was the primary outcome in the main analysis. In secondary analysis, VTE diagnosis was the primary exposure and in-hospital mortality the primary outcome.
    Results: Over the 13 months, 374,244 unique patients had a diagnosis of COVID-19 during a hospital stay, of whom 17,346 (4.6%) had a recorded diagnosis of VTE. VTE was more commonly recorded in patients aged 40-79 years, males and in patients of Black ethnicity, even after adjusting for covariates. Recorded VTE diagnosis was associated with longer hospital stay and higher adjusted in-hospital mortality (odds ratio 1.35 (95% confidence interval 1.29 to 1.41)).
    Conclusions: VTE was a common complication of hospitalisation with COVID-19 in England. VTE was associated with both increased length of stay and mortality rate.
    MeSH term(s) Adolescent ; Adult ; COVID-19/complications ; Hospitalization ; Humans ; Length of Stay ; Male ; Retrospective Studies ; Risk Factors ; Venous Thromboembolism/diagnosis ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/etiology
    Language English
    Publishing date 2022-03-24
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 121852-9
    ISSN 1879-2472 ; 0049-3848
    ISSN (online) 1879-2472
    ISSN 0049-3848
    DOI 10.1016/j.thromres.2022.03.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Venous thromboembolism after COVID-19 vaccination in patients with thrombophilia.

    Houghton, Damon E / Wysokinski, Waldemar E / Padrnos, Leslie J / Shah, Surbhi / Wysokinska, Ewa / Pruthi, Rajiv / Ghorbanzadeh, Atefeh / Ashrani, Aneel / Sridharan, Meera / McBane, Robert D / Padmanabhan, Anand / Casanegra, Ana I

    American journal of hematology

    2023  Volume 98, Issue 4, Page(s) 566–570

    Abstract: Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 ... thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and ... A total of 792 010 patients with at least one COVID-19 vaccination were identified. Six thousand sixty ...

    Abstract Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 vaccinations. The aim of this study was to examine VTE outcomes in patients with inherited or acquired thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE occurring 90 days before and after the date of the first vaccine dose. Thrombophilia patients were identified through laboratory testing results and ICD-10 codes. A total of 792 010 patients with at least one COVID-19 vaccination were identified. Six thousand sixty-seven of these patients were found to have a thrombophilia, among whom there was a total of 39 VTE events after compared to 51 VTE events before vaccination (0.64% vs. 0.84%, p = .20). In patients with Factor V Leiden or prothrombin gene mutation, VTE occurred in 27 patients before and in 29 patients after vaccination (0.61 vs. 0.65%, p = .79). In patients with antiphospholipid syndrome, VTE occurred in six patients before and four patients after vaccination (0.59% vs. 0.39%, p = .40). No difference was observed in the overall VTE rate when comparing the postvaccination 90 days to the prevaccination 90 days, adjusted hazard ratio 0.81 (95% confidence interval: 0.53-1.23). In this subgroup of COVID-19 vaccinated patients with thrombophilia, there was no increased risk for acute VTE postvaccination compared to the prevaccination timeframe. These results are consistent with prior studies and should offer additional reassurance to patients with inherited or acquired thrombophilia.
    MeSH term(s) Humans ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/etiology ; COVID-19 Vaccines/adverse effects ; COVID-19/complications ; COVID-19/prevention & control ; Thrombophilia/genetics ; Vaccination/adverse effects ; Risk Factors ; Factor V/genetics
    Chemical Substances COVID-19 Vaccines ; Factor V (9001-24-5)
    Language English
    Publishing date 2023-01-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26848
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Inflammation and Venous Thromboembolism in Hospitalized Patients with COVID-19.

    Liontos, Angelos / Biros, Dimitrios / Matzaras, Rafail / Tsarapatsani, Konstantina-Helen / Kolios, Nikolaos-Gavriel / Zarachi, Athina / Tatsis, Konstantinos / Pappa, Christiana / Nasiou, Maria / Pargana, Eleni / Tsiakas, Ilias / Lymperatou, Diamantina / Filippas-Ntekouan, Sempastien / Athanasiou, Lazaros / Samanidou, Valentini / Konstantopoulou, Revekka / Vagias, Ioannis / Panteli, Aikaterini / Milionis, Haralampos /
    Christaki, Eirini

    Diagnostics (Basel, Switzerland)

    2023  Volume 13, Issue 22

    Abstract: ... the association between inflammation and disease outcomes in adult hospitalized COVID-19 patients with VTE ... collected from COVID-19 patients hospitalized at the Infectious Diseases Unit (IDU ... Background: A link between inflammation and venous thromboembolism (VTE) in COVID-19 disease has ...

    Abstract Background: A link between inflammation and venous thromboembolism (VTE) in COVID-19 disease has been suggested pathophysiologically and clinically. The aim of this study was to investigate the association between inflammation and disease outcomes in adult hospitalized COVID-19 patients with VTE.
    Methods: This was a retrospective observational study, including quantitative and qualitative data collected from COVID-19 patients hospitalized at the Infectious Diseases Unit (IDU) of the University Hospital of Ioannina, from 1 March 2020 to 31 May 2022. Venous thromboembolism was defined as a diagnosis of pulmonary embolism (PE) and/or vascular tree-in-bud in the lungs. The burden of disease, assessed by computed tomography of the lungs (CTBoD), was quantified as the percentage (%) of the affected lung parenchyma. The study outcomes were defined as death, intubation, and length of hospital stay (LoS). A chi-squared test and univariate logistic regression analyses were performed in IBM SPSS 28.0.
    Results: After propensity score matching, the final study cohort included 532 patients. VTE was found in 11.2% of the total population. In patients with VTE, we found that lymphocytopenia and a high neutrophil/lymphocyte ratio were associated with an increased risk of intubation and death, respectively. Similarly, CTBoD > 50% was associated with a higher risk of intubation and death in this group of patients. The triglyceride-glucose (TyG) index was also linked to worse outcomes.
    Conclusions: Inflammatory indices were associated with VTE. Lymphocytopenia and an increased neutrophil-to-lymphocyte ratio negatively impacted the disease's prognosis and outcomes. Whether these indices unfavorably affect outcomes in COVID-19-associated VTE must be further evaluated.
    Language English
    Publishing date 2023-11-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662336-5
    ISSN 2075-4418
    ISSN 2075-4418
    DOI 10.3390/diagnostics13223477
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.

    Amani-Beni, Reza / Kermani-Alghoraishi, Mohammad / Darouei, Bahar / Reid, Christopher M

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

    2023  Volume 75, Issue 1, Page(s) 72

    Abstract: ... use for post-discharge COVID-19 patients. We aimed to systematically review the current literature ... selection of the ideal AC regarding extended thromboprophylaxis for post-discharge COVID-19 patients ... hospitalized COVID-19 patients, with 19.25% receiving extended thromboprophylaxis. VTE events ranging from 0 ...

    Abstract Background: Coronavirus disease of 2019 (COVID-19) is associated with venous thromboembolism (VTE), not only during hospitalization but also after discharge, raising concerns about anticoagulant (AC) use for post-discharge COVID-19 patients. We aimed to systematically review the current literature on the possible benefits or risks regarding extended thromboprophylaxis.
    Main body: We searched related databases from December 1, 2019, to October 6, 2022, including studies on the necessity, duration, and selection of the ideal AC regarding extended thromboprophylaxis for post-discharge COVID-19 patients. The screening of the selected databases led to 18 studies and 19 reviews and guidelines. Studies included 52,927 hospitalized COVID-19 patients, with 19.25% receiving extended thromboprophylaxis. VTE events ranging from 0 to 8.19% (median of 0.7%) occurred in a median follow-up of 49.5 days. All included studies and guidelines, except four studies, recommended post-discharge prophylaxis after an individual risk assessment indicating high thrombotic and low bleeding risk. Studies used risk assessment models (RAMs), clinical evaluation, and laboratory data to identify COVID-19 patients with a high risk of VTE. IMPROVE-DD was the most recommended RAM. Direct oral anticoagulants (DOACs) and low molecular weight heparins (LMWHs) were the most used AC classes.
    Conclusions: Post-discharge prophylaxis for COVID-19 patients is recommended after an individual assessment. The IMPROVE-DD model can help predict VTE risk. After distinguishing patients who need post-discharge AC therapy, DOACs for 30-35 days and LMWHs for 40-45 days can be the drug of choice. Further studies, particularly the results of the ongoing randomized controlled trials (RCTs), are required. Also, to properly handle such patients, every physician should consider lifestyle modification in addition to pharmacological treatment for post-discharge VTE prophylaxis.
    Language English
    Publishing date 2023-08-18
    Publishing country Germany
    Document type Journal Article ; Review
    ISSN 2090-911X
    ISSN (online) 2090-911X
    DOI 10.1186/s43044-023-00400-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19.

    Fang, Margaret C / Reynolds, Kristi / Tabada, Grace H / Prasad, Priya A / Sung, Sue Hee / Parks, Anna L / Garcia, Elisha / Portugal, Cecilia / Fan, Dongjie / Pai, Ashok P / Go, Alan S

    JAMA network open

    2023  Volume 6, Issue 3, Page(s) e232338

    Abstract: Importance: Patients hospitalized with COVID-19 have higher rates of venous thromboembolism (VTE ... VTE risk; these findings may help identify subsets of patients with COVID-19 who may benefit from more ... with COVID-19, the absolute risk of VTE was low. Several patient-level factors were associated with higher ...

    Abstract Importance: Patients hospitalized with COVID-19 have higher rates of venous thromboembolism (VTE), but the risk and predictors of VTE among individuals with less severe COVID-19 managed in outpatient settings are less well understood.
    Objectives: To assess the risk of VTE among outpatients with COVID-19 and identify independent predictors of VTE.
    Design, setting, and participants: A retrospective cohort study was conducted at 2 integrated health care delivery systems in Northern and Southern California. Data for this study were obtained from the Kaiser Permanente Virtual Data Warehouse and electronic health records. Participants included nonhospitalized adults aged 18 years or older with COVID-19 diagnosed between January 1, 2020, and January 31, 2021, with follow-up through February 28, 2021.
    Exposures: Patient demographic and clinical characteristics identified from integrated electronic health records.
    Main outcomes and measures: The primary outcome was the rate per 100 person-years of diagnosed VTE, which was identified using an algorithm based on encounter diagnosis codes and natural language processing. Multivariable regression using a Fine-Gray subdistribution hazard model was used to identify variables independently associated with VTE risk. Multiple imputation was used to address missing data.
    Results: A total of 398 530 outpatients with COVID-19 were identified. The mean (SD) age was 43.8 (15.8) years, 53.7% were women, and 54.3% were of self-reported Hispanic ethnicity. There were 292 (0.1%) VTE events identified over the follow-up period, for an overall rate of 0.26 (95% CI, 0.24-0.30) per 100 person-years. The sharpest increase in VTE risk was observed during the first 30 days after COVID-19 diagnosis (unadjusted rate, 0.58; 95% CI, 0.51-0.67 per 100 person-years vs 0.09; 95% CI, 0.08-0.11 per 100 person-years after 30 days). In multivariable models, the following variables were associated with a higher risk for VTE in the setting of nonhospitalized COVID-19: age 55 to 64 years (HR 1.85 [95% CI, 1.26-2.72]), 65 to 74 years (3.43 [95% CI, 2.18-5.39]), 75 to 84 years (5.46 [95% CI, 3.20-9.34]), greater than or equal to 85 years (6.51 [95% CI, 3.05-13.86]), male gender (1.49 [95% CI, 1.15-1.96]), prior VTE (7.49 [95% CI, 4.29-13.07]), thrombophilia (2.52 [95% CI, 1.04-6.14]), inflammatory bowel disease (2.43 [95% CI, 1.02-5.80]), body mass index 30.0-39.9 (1.57 [95% CI, 1.06-2.34]), and body mass index greater than or equal to 40.0 (3.07 [1.95-4.83]).
    Conclusions and relevance: In this cohort study of outpatients with COVID-19, the absolute risk of VTE was low. Several patient-level factors were associated with higher VTE risk; these findings may help identify subsets of patients with COVID-19 who may benefit from more intensive surveillance or VTE preventive strategies.
    MeSH term(s) Adult ; Humans ; Male ; Female ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/etiology ; Venous Thromboembolism/prevention & control ; Cohort Studies ; Retrospective Studies ; COVID-19 Testing ; COVID-19/complications ; COVID-19/epidemiology
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.2338
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Characteristics, Outcomes, and Associations of Venous Thromboembolism in Diabetic Patients Infected With COVID-19 in Riyadh, Saudi Arabia.

    Albabtain, Mansour S / Alyousef, Khalid A / Alharbi, Ziad M / Almutairi, Mohammed N / Jawdat, Dunia

    Cureus

    2024  Volume 16, Issue 5, Page(s) e59468

    Abstract: ... COVID-19 patients remain ambiguous in the literature, with some conflicting findings, especially ... exploring the incidence, lab findings, and outcomes of VTE among hospitalized COVID-19 patients known ... significantly associated with the development of VTE in COVID-19 patients. Conclusions Based on our study ...

    Abstract Background The associations and risk factors for venous thromboembolism (VTE) among hospitalized COVID-19 patients remain ambiguous in the literature, with some conflicting findings, especially in Saudi Arabia. In this study, we aim to elaborate on these data by examining regional patient populations and exploring the incidence, lab findings, and outcomes of VTE among hospitalized COVID-19 patients known to have diabetes mellitus (DM). Methodology This cross-sectional study was conducted at King Abdulaziz Medical City in Riyadh. The BestCare system was used to collect patients' data between September 2020 and February 2022. JMP15 was used for data analysis. Frequencies and percentages were used for categorical data, and median and interquartile ranges were used for quantitative data. The chi-square and Kruskal-Wallis rank-sum tests were used to assess the difference between categorical and quantitative variables, respectively. Nominal logistical regression was used to assess diabetes as a risk factor for developing VTE among COVID-19 patients. Results Data from 153 admitted patients were collected after they satisfied the inclusion criteria. Of these patients, 39 (25.49%) developed VTE. The demographic data included age group, gender, and DM status presented as frequencies and percentages. Through bivariate analysis, patients with longer hospital stays had at least one episode of VTE (p = 0.0072). Using nominal logistic regression analysis, diabetes as a risk factor (odds ratio = 4.11, confidence interval = 0.955-5.05, p = 0.0287) was significantly associated with the development of VTE in COVID-19 patients. Conclusions Based on our study, diabetes proved significant when evaluating the possible factors regarding VTE development in COVID-19 patients. In addition, the length of stay also played a critical role in the severity of VTE in COVID-19 patients. Similar studies should be conducted on a national scale in Saudi Arabia to accomplish two goals: first, to gain further understanding of the impact of the variables investigated in our population, and second, to publish data that are more generalizable to the larger population of Saudi Arabia.
    Language English
    Publishing date 2024-05-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.59468
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study.

    Jara-Palomares, Luis / Bikdeli, Behnood / Jiménez, David / Muriel, Alfonso / Demelo-Rodríguez, Pablo / Moustafa, Farès / Villalobos, Aurora / López-Miguel, Patricia / López-Jiménez, Luciano / Otálora, Sonia / Peris, María Luisa / Amado, Cristina / Chopard, Romain / Rivera-Cívico, Francisco / Monreal, Manuel

    EClinicalMedicine

    2024  Volume 73, Page(s) 102659

    Abstract: ... anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence rates and ... mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19 ... Among 1106 patients with COVID-19-associated VTE (age 62.3 ± 14.4 years; 62.9% male) followed-up for 12.5 ...

    Abstract Background: The clinical relevance of recurrent venous thromboembolism (VTE) after discontinuing anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence rates and mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19-associated VTE.
    Methods: A prospective, multicenter, non-interventional study was conducted between March 25, 2020, and July 26, 2023, including patients who had discontinued anticoagulation after at least 3 months of therapy. All patients from the registry were analyzed during the study period to verify inclusion criteria. Patients with superficial vein thrombosis, those who did not receive at least 3 months of anticoagulant therapy, and those who were followed for less than 15 days after discontinuing anticoagulation were excluded. Outcomes were: 1) Incidence rates of symptomatic VTE recurrences, and 2) fatal PE. The rate of VTE recurrences was defined as the number of patients with recurrent VTE divided by the patient-years at risk of recurrent VTE during the period when anticoagulation was discontinued.
    Findings: Among 1106 patients with COVID-19-associated VTE (age 62.3 ± 14.4 years; 62.9% male) followed-up for 12.5 months (p25-75, 6.3-20.1) after discontinuing anticoagulation, there were 38 VTE recurrences (3.5%, 95% confidence interval [CI]: 2.5-4.7%), with a rate of 3.1 per 100 patient-years (95% CI: 2.2-4.2). No patient died of recurrent PE (0%, 95% CI: 0-7.6%). Subgroup analyses showed that patients with diagnosis in 2021-2022 (vs. 2020) (Hazard ratio [HR] 2.86; 95% CI 1.45-5.68) or those with isolated deep vein thrombosis (vs. pulmonary embolism) (HR 2.31; 95% CI 1.19-4.49) had significantly higher rates of VTE recurrences.
    Interpretation: In patients with COVID-19-associated VTE who discontinued anticoagulation after at least 3 months of treatment, the incidence rate of recurrent VTE and the case-fatality rate was low. Therefore, it conceivable that long-term anticoagulation may not be required for many patients with COVID-19-associated VTE, although further research is needed to confirm these findings.
    Funding: Sanofi and Rovi, Sanofi Spain.
    Language English
    Publishing date 2024-05-25
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2024.102659
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top